Sharing is Caring!
‘CSL says it is paying $US200 million ($A312m) up-front to license next-generation mRNA vaccine technology from a small US company.
CSL said on Wednesday its CSL Seqirus subsidiary, the second-biggest flu vaccine manufacturer globally, has licensed the technology from NASDAQ-listed Arcturus Therapeutics.
The $US485m NASDAQ-listed company would be eligible to receive more than $US4.3 billion ($A6.7 billion) in milestone payments, plus double-digit royalties under the terms of the deal.’
au.finance.yahoo.com/news/csl-paying-312m-license-mrna-004120691.html
See also S.F. is spending $1.7 million on one public toilet: What are they making it out of — gold?
Trending:
See also SEC Awards More Than $10 Million to Whistleblower.
Views: 2